(Q37094765)

18 August 2017

1 reference

title

Use of vascular ultrasound in clinical trials to evaluate new cardiovascular therapies (English)

1 reference

18 August 2017

1 reference

David T Nash

1

1 reference

18 August 2017

publication date

1 February 2008

1 reference

Journal of the National Medical Association

18 August 2017

published in

1 reference

18 August 2017

volume

100

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

222-229

1 reference

A population perspective on diabetes prevention: whom should we target for preventing weight gain?

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Prognostic significance of progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Compensatory enlargement of human atherosclerotic coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Extent and direction of arterial remodeling in stable versus unstable coronary syndromes : an intravascular ultrasound study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Discrepancies Between Cineangiographic and Postmortem Findings in Patients with Coronary Artery Disease and Recent Myocardial Revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Prevention Conference V : Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Noninvasive Tests of Atherosclerotic Burden : Writing Group III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Safety of intracoronary ultrasound: data from a Multicenter European Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

The safety of intracoronary ultrasound. A multicenter survey of 2207 examinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

The role of carotid arterial intima-media thickness in predicting clinical coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Atherosclerotic disease regression with statins: studies using vascular markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effects of torcetrapib in patients at high risk for coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Effect of torcetrapib on the progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2931210-4

10.1016/S0027-9684(15)31210-4

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference